GlassScriptPhysician profile
Peter Chang
NPI 1568451797
$655,629.51
in general payments reported to CMS, 2019-2025
27 companies · $118K in 2025
The $118K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $29K · 2021: $91K · 2022: $127K · 2023: $125K · 2024: $115K · 2025: $118K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $279K · Travel and Lodging: $31K · Food and Beverage: $21K · Consulting Fee: $17K · Honoraria: $7,700 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $279,000.00 |
| Travel and Lodging | $31,403.38 |
| Food and Beverage | $20,807.18 |
| Consulting Fee | $17,187.50 |
| Honoraria | $7,700.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378,707.52 | 2021-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Allergan, INC. | $158,572.88 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $53,479.28 | 2019-2021 | |
| Alcon Vision LLC | $25,074.59 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| New World Medical,INC. | $20,136.06 | 2019-2025 | Ahmed Glaucoma Valve, Clearpath, Streamline |
| Glaukos Corporation | $9,623.83 | 2019-2025 | Travoprost Intraocular Implant - Idose, Idosetr, Idose |
| Dompe US, INC. | $2,275.00 | 2023 | Oxervate |
| Eyepoint US, INC. | $1,782.29 | 2021-2022 | |
| Sight Sciences, INC. | $1,295.53 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $751.12 | 2022-2025 | Vyzulta, Miebo, Envista Envy Iol |
| Optos, INC. | $594.32 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $546.79 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $464.41 | 2021-2025 | Tecnis Iol, Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $453.11 | 2024-2025 | Xdemvy |
| Iridex Corporation | $344.24 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $277.30 | 2023-2024 | |
| Globus Medical, INC. | $266.85 | 2021 | |
| Beaver-Visitec International, INC. | $156.90 | 2023-2025 | |
| Ivantis, INC | $154.12 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $148.13 | 2022 | |
| Ocular Therapeutix, INC. | $125.75 | 2023-2025 | Dextenza |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Alimera Sciences, INC. | $112.65 | 2019 | |
| Sun Pharmaceutical Industries INC. | $110.50 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $17.00 | 2025 | Tepezza |
| Thea Pharma INC. | $14.94 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.